US FDA Eyes Ways To Improve Conduct, Mitigate Bias In Open-Label Cancer Studies

 
• By Sue Sutter
Balancing rocks
The oncology clinical trial community must consider how to balance hope of promising new treatments with the preapproval hype from early study results. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers